Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia: A Randomized Controlled Trial | Cardiology | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group.  Natural history of aortic and coronary atherosclerotic lesions in youth: findings from the PDAY Study.  Arterioscler Thromb.1993;13:1291-1298.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8364013&dopt=AbstractGoogle Scholar
2.
Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group.  Relationship of atherosclerosis in young men to serum lipoprotein cholesterol concentrations and smoking.  JAMA.1990;264:3018-3024.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2243430&dopt=AbstractGoogle Scholar
3.
Kwiterovich Jr PO, Frederickson DS, Levi RI. Neonatal diagnosis of familial type-II hyperlipoproteinemia.  Lancet.1973;1:118-121.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4118465&dopt=AbstractGoogle Scholar
4.
Kwiterovich Jr PO, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia): a study of its biochemical, genetic, and clinical presentation in childhood.  J Clin Invest.1974;53:1237-1249.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4363406&dopt=AbstractGoogle Scholar
5.
De Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJP, Stroes ESG. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia.  Atherosclerosis.2002;163:193-197.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12048139&dopt=AbstractGoogle Scholar
6.
Pauciullo P, Iannuzzi A, Sartorio R.  et al.  Increased intima-media thickness of the common carotid artery in hypercholesterolemic children.  Arterioscler Thromb.1994;14:1075-1079.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8018662&dopt=AbstractGoogle Scholar
7.
Tonstad S, Joakimson O, Stensland-Bugge E.  et al.  Risk factors related to intima-media thickness in children with familial hypercholesterolemia and control subjects.  Arterioscler Thromb Vasc Biol.1996;16:984-991.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8696963&dopt=AbstractGoogle Scholar
8.
Jarvisalo MJ, Jartti L, Nanto-Salonen K.  et al.  Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children.  Circulation.2001;104:2943-2947.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11739310&dopt=AbstractGoogle Scholar
9.
Wiegman A, De Groot E, Hutten BA.  et al.  Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia.  Lancet.2004;363:369-370.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15070569&dopt=AbstractGoogle Scholar
10.
Mabuchi H, Koizumi J, Shimizu M, Takeda R..Hokuriky FH-CHD Study Group.  Development of coronary heart disease in familial hypercholesterolemia.  Circulation.1989;79:225-232.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2914343&dopt=AbstractGoogle Scholar
11.
Mouratidis B, Vaughan-Neil EF, Gilday DL.  et al.  Detection of silent coronary artery disease in adolescents and young adults with familial hypercholesterolemia by single-photon emission computed tomography thallium-201 scanning.  Am J Cardiol.1992;70:1109-1112.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1414930&dopt=AbstractGoogle Scholar
12.
Knipscheer HC, Boelen CCA, Kastelein JJP.  et al.  Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.  Pediatr Res.1996;39:867-871.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8726243&dopt=AbstractGoogle Scholar
13.
Lambert M, Lupien PJ, Cagne C.  et al. Canadian Lovastatin in Children Study Group.  Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin.  Pediatrics.1996;97:619-628.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8628597&dopt=AbstractGoogle Scholar
14.
Stein EA, Illingworth DR, Kwiterovich Jr PO.  et al.  Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial.  JAMA.1999;281:137-144.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9917116&dopt=AbstractGoogle Scholar
15.
De Jongh S, Ose L, Szamosi T.  et al.  Efficacy and safety of statin therapy in children with familial hypercholesterolemia.  Circulation.2002;106:2231-2237.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12390953&dopt=AbstractGoogle Scholar
16.
De Jongh S, Lilien MR, Op‘t Roodt J, Stroes ES, Bakker HD, Kastelein JJP. Early statin therapy restores endothelial function in children with familial hypercholesterolemia.  J Am Coll Cardiol.2002;40:2117-2121.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12505222&dopt=AbstractGoogle Scholar
17.
O'Leary DH, Polak JF, Kronwal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults.  N Engl J Med.1999;340:14-22.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9878640&dopt=AbstractGoogle Scholar
18.
Hodis HN, Mack WJ, LaBree L.  et al.  The role of carotid arterial intima-media thickness in predicting clinical coronary events.  Ann Intern Med.1998;128:262-269.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9471928&dopt=AbstractGoogle Scholar
19.
Chambless LE, Heiss G, Folsom AR.  et al.  Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993.  Am J Epidemiol.1997;146:483-494.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9290509&dopt=AbstractGoogle Scholar
20.
Wiegman A, Rodenburg J, de Jongh S.  et al.  Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children.  Circulation.2003;107:1473-1478.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12654602&dopt=AbstractGoogle Scholar
21.
Voedingsraad.  Nederlandse Voedingsnormen 19892nd ed. The Hague, the Netherlands: Voedingsraad; 1992.
22.
Voedingscentrum.  Zo eet Nederland, resultaten van de Voedselconsumptiepeiling 1998. 3rd ed. The Hague, the Netherlands: Voedingscentrum; 1998.
23.
Van Dam M, de Groot E, Clee SM.  et al.  Association between increased arterial wall thickness and impairment in ABCA1 driven cholesterol efflux; an observational study.  Lancet.2002;359:37-41.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11809185&dopt=AbstractGoogle Scholar
24.
Warnick GR, Knopp RH, Fitzpatrick V, Branson L. Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints.  Clin Chem.1990;36:15-19.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2297909&dopt=AbstractGoogle Scholar
25.
Fouchier SW, Defesche JC, Umans-Eckenhausen MAW, Kastelein JJP. The molecular basis of familial hypercholesterolemia in the Netherlands.  Hum Genet.2001;109:602-615.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11810272&dopt=AbstractGoogle Scholar
26.
Haycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults.  J Pediatr.1978;93:62-66.http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query?db=m&form=6&Dopt=r&uid=entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=650346&dopt=AbstractGoogle Scholar
Original Contribution
July 21, 2004

Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia: A Randomized Controlled Trial

Author Affiliations

Author Affiliations: Departments of Vascular Medicine (Drs Wiegman, de Groot, Rodenburg, Büller, Sijbrands, and Kastelein), Paediatrics (Drs Wiegman and Bakker), and Clinical Epidemiology and Biostatistics (Dr Hutten), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Internal Medicine, Erasmus Medical Center, University of Rotterdam, Rotterdam, the Netherlands (Dr Sijbrands).

JAMA. 2004;292(3):331-337. doi:10.1001/jama.292.3.331
Abstract

Context Children with familial hypercholesterolemia have endothelial dysfunction and increased carotid intima-media thickness (IMT), which herald the premature atherosclerotic disease they develop later in life. Although intervention therapy in the causal pathway of this disorder has been available for more than a decade, the long-term efficacy and safety of cholesterol-lowering medication have not been evaluated in children.

Objective To determine the 2-year efficacy and safety of pravastatin therapy in children with familial hypercholesterolemia.

Design Randomized, double-blind, placebo-controlled trial that recruited children between December 7, 1997, and October 4, 1999, and followed them up for 2 years.

Setting and Participants Two hundred fourteen children with familial hypercholesterolemia, aged 8 to 18 years and recruited from an academic medical referral center in the Netherlands.

Intervention After initiation of a fat-restricted diet and encouragement of regular physical activity, children were randomly assigned to receive treatment with pravastatin, 20 to 40 mg/d (n = 106), or a placebo tablet (n = 108).

Main Outcome Measures The primary efficacy outcome was the change from baseline in mean carotid IMT compared between the 2 groups over 2 years; the principal safety outcomes were growth, maturation, and hormone level measurements over 2 years as well as changes in muscle and liver enzyme levels.

Results Compared with baseline, carotid IMT showed a trend toward regression with pravastatin (mean [SD], −0.010 [0.048] mm; P = .049), whereas a trend toward progression was observed in the placebo group (mean [SD], +0.005 [0.044] mm; P = .28). The mean (SD) change in IMT compared between the 2 groups (0.014 [0.046] mm) was significant (P = .02). Also, pravastatin significantly reduced mean low-density lipoprotein cholesterol levels compared with placebo (−24.1% vs +0.3%, respectively; P<.001). No differences were observed for growth, muscle or liver enzymes, endocrine function parameters, Tanner staging scores, onset of menses, or testicular volume between the 2 groups.

Conclusion Two years of pravastatin therapy induced a significant regression of carotid atherosclerosis in children with familial hypercholesterolemia, with no adverse effects on growth, sexual maturation, hormone levels, or liver or muscle tissue.

×